Brand Name

Flavoxate

View Brand Information
FDA approval date: December 22, 2004
Classification: Cholinergic Muscarinic Antagonist
Form: Tablet

What is Flavoxate?

Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle.
Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle.
Journal: Biological & pharmaceutical bulletin
Published: October 29, 2025
Harnessing Chromone as a Versatile Scaffold for Emerging Biological Applications: Recent Advances and Medicinal Insights.
Harnessing Chromone as a Versatile Scaffold for Emerging Biological Applications: Recent Advances and Medicinal Insights.
Journal: Chemical record (New York, N.Y.)
Published: March 14, 2025
Exploring the selective inhibitory effects of Flavoxate and its analogues on two chloride channels and neuronal action potentials.
Exploring the selective inhibitory effects of Flavoxate and its analogues on two chloride channels and neuronal action potentials.
Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
Published: February 17, 2025
View All Latest Advances